We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Merck’s Keytruda Doubles Survival Rate in Phase 3 Lung Cancer Study
Merck’s Keytruda Doubles Survival Rate in Phase 3 Lung Cancer Study
Merck said its blockbuster cancer drug Keytruda (pembrolizumab) doubled patients’ five-year survival rate compared to chemotherapy in a late-stage trial as a first-line treatment for metastatic nonsmall-cell lung cancer (NSCLC).